Method for detecting and quantifying biological species of interest by metagenome analysis taking into account calibrators
By adding calibrators and control species to the sample, combined with metagenomic analysis and bioinformatics steps, the complexity and difficulty of quantification of PCR technology in the detection of multiple biological species is solved, and the accurate quantification of biological species of interest is achieved. Reliability of the detection and analysis process.
Patent Information
- Application Number
- CN202411283591.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2019-07-23
- Filing Date
- 2020-07-22
- Publication Date
- 2024-11-05
AI Technical Summary
Existing PCR techniques are complex and require prior knowledge when detecting multiple biological species. Metagenomic analysis can identify multiple biological species without prior knowledge, but it is difficult to conduct quantitative analysis.
Quantitative detection of biological species of interest is achieved by adding calibrators to the sample, performing metagenomic analysis and sequencing, and using bioinformatics steps to determine the concentration of biological species of interest, and combining control species for quality control and calibration.
Quantitative detection of various biological species without prior knowledge is achieved, the accuracy and efficiency of the detection is improved, and the accuracy and reliability of the metagenomic analysis process is ensured.
Smart Images

Figure CN118895348A_ABST
Abstract
Description
[0001] This application is a divisional application of Chinese patent application No. 202080065816.6, filed on July 22, 2020, entitled “Method for detecting and quantifying biological species of interest through metagenomic analysis taking into account calibrators”. Technical Field
[0002] The technical field of the present invention is the identification of biological species of interest through metagenomic analysis. Prior art
[0003] Amplification of nucleic acids by polymerase chain reaction (PCR) allows for rapid and early diagnosis of the presence of certain microorganisms in a sample. For example, PCR is particularly suitable for detecting deoxyribonucleic acid (DNA) of bacteria that are difficult to culture or slow to develop, such as Mycobacterium tuberculosis.
[0004] However, the implementation of PCR requires the use of primers that specifically target genes present in the target biological species. PCR therefore allows the specific analysis of one biological species, which makes it a sensitive, selective and quantitative method. However, it assumes prior knowledge of the target biological species. If multiple biological species are to be sought, so-called multiplex PCR must be performed, which makes the process more complicated.
[0005] It is also possible to target genes that are present in a variety of target biological species. In the case of bacteria, for example, the 16S RNA gene may be involved. The PCR analysis is then said to be broad-range. However, broad-range PCR is more difficult to implement and assumes that prior knowledge about the target biological species to be identified is available. The targeting of genes is described in EP2985350 or This is described in the publication “Adjusting microbiome profiles for differences in microbial load by spike-inbacteria”, Microbiome (2016) 4, 28.
[0006] In contrast to the above techniques, metagenomics allows the sequencing of the genomes of multiple individuals of different biological species in a given culture. It is then possible to determine the species actually present in the sample and their relative abundance. Metagenomics sequences the genomes of multiple individuals of different species in a given culture and does so without prior knowledge of the biological species in the sample, whether they are bacteria, viruses or humans. An analysis of the various genomes of biological species in the sample is thus obtained. It is then possible to determine which species are present, and their relative abundance.
[0007] The field of sequencing has recently progressed with the advent of second and third generation sequencing technologies HTS technologies, where HTS stands for high throughput sequencing. The power of bioinformatics has been improved, which allows for rapid computational processing of the biological information generated by sequencing. Currently, high throughput sequencing allows the generation of enough sequences to obtain a representative list of the various species present in a sample. It is a commercially available analytical method and its application has become relatively common. Document WO2018 / 069430 describes the use of metagenomic analysis in the identification of pathogens and antibiotic resistance markers.
[0008] The publication “Clinical metagenomics of bone and joint infections: a proof of concept study” by Ruppé E also describes the use of metagenomics for bacterial identification. Document WO 2017 / 053446 and the publication “Validation of metagenomic next-generation sequencing tests for universal pathogen detection” by Schlaberg describe metagenomic methods for analyzing samples, in which internal controls formed by known biological species are introduced into the sample.
[0009] The inventors provide a method for detecting and potentially quantifying a biological species of interest or even a plurality of biological species of interest in a sample by performing metagenomic analysis on the sample. In addition, the method allows the establishment of indicators that can determine whether the biological or bioinformatics steps of the metagenomic process are performed correctly. Summary of the invention
[0010] A subject of the present invention is a method for detecting a biological species of interest that may be present in an analysis sample, the biological species of interest having a known or partially known genome, the analysis sample comprising a mixture of a plurality of biological species, the method comprising the following steps:
[0011] a) extracting nucleic acid from an analysis sample;
[0012] b) sequencing the nucleotide sequence extracted in step a);
[0013] c) Based on the sorting results:
[0014] (i) assigning the sequence generated in step b) based on a sequence reference database;
[0015] ii) determining the amount of sequences assigned to the biological species of interest;
[0016] The method is characterized in that it comprises adding a calibrator to the analysis sample before step b), the calibrator being a biological species added at a known concentration, the calibrator having a known genome, and step c) comprises:
[0017] (iii) determining the amount of sequence assigned to the calibrator;
[0018] d) estimating the concentration of the biological species of interest in the sample based on the sequence quantities estimated in steps (ii) and (iii).
[0019] Preferably, in sub-steps ii) and iii), the sequence quantities assigned to the biological species of interest and the reference biological species, respectively, are normalized by a reference quantity. The reference quantity may for example be the total amount of sequences generated during sequencing.
[0020] The method may include considering a decision threshold to which the concentration of the species of interest is compared.
[0021] The decision threshold is preferably expressed in units corresponding to the number of sequences per unit volume (or per unit weight), for example in genome equivalents per milliliter.The decision threshold may depend on the biological species in question.
[0022] Preferably, the calibrant has one of the following features, implemented individually or in a technically achievable combination:
[0023] - The genome size of the calibrator is 0.1 to 10 times the genome size of the biological species of interest;
[0024] - For samples containing an endogenous organism, the calibrator has a different genome than the endogenous organism;
[0025] - the concentration of the calibrator is 0.001 to 1000 times, preferably 0.01 to 100 times, the determination threshold under consideration;
[0026] - When the biological species of interest is bacteria, the calibrant has an intact membrane or cell wall;
[0027] - When the biological species of interest is a virus, the calibrant has a protein coat;
[0028] The genome of the calibrator has GC (guanine-cytosine) bases that are 75% to 125% of the amount of GC (guanine-cytosine) bases of the genome of the biological species of interest.
[0029] Step d) may include:
[0030] - determining a first ratio between the amounts of the sequences respectively assigned to the biological species of interest and to the calibrator;
[0031] - determining a second ratio between the calibrator and the respective genome size of the biological species of interest;
[0032] - Consider the concentration of calibrants added to the analyzed samples.
[0033] Estimation of the concentration of the biological species of interest may thus include calculating the result of multiplying the first ratio by the second ratio and the concentration of the calibrator added to the analysis sample.
[0034] Step d) may include:
[0035] - Determine the coverage of biological species of interest and calibrants;
[0036] - calculating the ratio between the coverage determined for the biological species of interest and the coverage determined for the calibrator;
[0037] -Multiply the ratio thus calculated by the concentration of the calibrant added to the sample.
[0038] The method may include, after step d), a step e) of taking into account a decision threshold and comparing the concentration obtained in step d) with the decision threshold.
[0039] Other advantages and features will become more apparent from the following description of particular embodiments of the invention, which are provided by way of non-limiting examples and are illustrated in the following figures. BRIEF DESCRIPTION OF THE DRAWINGS
[0040] Figure 1 The main steps of the method according to the invention are schematically shown.
[0041] Figure 2A Shown is a quantitative comparison of the biological species of interest, in fact Staphylococcus aureus, obtained by carrying out the steps described below (y-axis) and a reference method using culture (x-axis).
[0042] Figure 2B Shown is a quantitative comparison of the biological species of interest, in fact Staphylococcus aureus, obtained by implementing the steps described below (y-axis) and a reference method using quantitative PCR (x-axis), respectively.
[0043] Figure 3 Shown are the statistical distributions of normalized sequence quantities corresponding to each biological species of interest, respectively, as measured in a test sample believed not to contain the biological species of interest.
[0044] Figure 4 is a graph showing a comparison between the concentrations of target biological species estimated by culture (x-axis) and by metagenomic analysis (y-axis), respectively. DETAILED DESCRIPTION
[0045] The purpose of the method is to be able to detect the presence of a biological species of interest SOI in a sample. The acronym SOI stands for "species of interest". In the case of detection, the method may allow a complete quantification of the species of interest SOI so as to allow a comparison with a decision threshold SD.
[0046] Biological species refers to microorganisms such as bacteria or viruses, fungi, archaea, amoeba, protists or microalgae. Biological species can also be cells or any other organism or entity containing nucleic acid sequences.
[0047] When the sample is obtained from a human or animal organism, the biological species of interest may be a pathogenic species. When the sample is obtained by sampling from an industrial process or the environment, the biological species of interest may be a species considered a contaminant, or an important species of interest in the industrial process or the environment, and its presence or concentration needs to be determined.
[0048] The species of interest has a known or partially known genome. The genome or a known fragment thereof consists of a sequence called a sequence of interest.
[0049] The method can treat multiple species of interest simultaneously. Thus, the term "species of interest" is to be interpreted as meaning at least one species of interest.
[0050] The determination threshold SD refers to a threshold value that can characterize the load of a biological species of interest, such as a microorganism, according to the target application. For example, it is set according to regulatory, sanitary or industrial restrictions. For example, when the application is used to assist clinical diagnosis, the biological species of interest is bacteria, and the determination threshold can be a concentration below which the presence of bacteria corresponds to colonization, i.e., non-pathological development, and above which the presence of bacteria is considered pathological, such as corresponding to infection. When the present invention is applied to an industrial process, the determination threshold corresponds to a pass value, so that samples above the determination threshold are considered not to pass, and samples below the determination threshold are considered to pass. Regardless of the application, when the concentration of the biological species of interest is higher than or equal to the determination threshold, it is defined as severe (clinical). In certain applications, such as in the manufacture of fermented products, if the concentration of the biological species of interest is lower than the determination threshold, it may be considered severe, the latter corresponding to the minimum acceptable concentration of the biological species.
[0051] Sample is usually the sample sampled from environment or dead or alive organism or even from manufactured goods or the product relevant to food production.For process control, sample can also be sampled from industrial facilities.Therefore, sample comprises various biological species that do not have the same genome.Particularly when sample is from sampling of organism such as human or animal organism, sample comprises a large number of cells derived from sample organism, and these cells may even constitute the overwhelming majority of sample.The genome of human or animal organism is 1000 to 100000 times larger than the genome of prokaryotic organism.In addition, sample usually comprises biological species that are naturally present in sample and are not easy to cause pathology or serious pollution.For example, when sample is bronchoalveolar sample, it comprises bacterial clusters that are naturally present in lung.When sample is fecal sample, it comprises bacterial clusters that are naturally present in digestive tract.Therefore, when biological species of interest is bacterium or virus, the nucleic acid of biological species of interest may be the minority of nucleic acid in sample.
[0052] Samples contain species that can be referred to as "matrix," which are endogenous to the sample and tend to mask metagenomic information associated with the biological species of interest. For example, when a sample is taken from yogurt, a piece of meat, or a vaccine, it includes matrix species representing these media. In the case of samples taken from an organism, the matrix contains the constituent cells of the organism.
[0053] An important aspect of the present invention is that according to the principle of metagenomic analysis, the sample undergoes extraction of nucleic acid (DNA and / or RNA), followed by a sequencing process. An amplification process may be performed before the sequencing process. Sequencing may be whole genome sequencing (WGS), especially whole genome shotgun sequencing. Thus a list of gene sequences of various species of the sample is obtained. All or nearly all nucleic acids of various species of the sample are sequenced using a high-throughput sequencing method. Then, bioinformatics means allow identification of the sequence of interest associated with the biological species of interest, and determine its amount, typically its normalized amount, as described below. Bioinformatics means are based on a sequence reference database, such as a complete reference genome in the WGS process as described above. The database includes at least all or part of the genome of the biological species of interest potentially present in the sample. It also includes all or part of the genome of the biological species referred to as a control species, which is described below.
[0054] Thus, using this technique, a description of the genomes of the various species of the sample is obtained by sequencing. Next, among the genomic sequences listed, the sequences corresponding to the biological species of interest and the sequences corresponding to the reference species are identified.
[0055] The method includes the following references Figure 1 Describe the steps.
[0056] Step 10 :sampling.
[0057] In this example, the sample is taken from a living human organism to aid in diagnosis. However, the invention is not limited to application in the field of living organisms. The sample can be taken from an industrial or hospital environment to verify consistency with respect to the decision threshold.
[0058] Step 20 : Add control species.
[0059] One of the purposes of the present invention is to assess to what extent metagenomic analysis is available. In particular, it involves assessing the consistency of all steps from sample preparation, sample exclusion to bioinformatic analysis of sequencing data. To this end, a control species is added to the sample, which is denoted SPC, an acronym for sample processing control. One function of the control species is to allow checking whether the steps of extracting nucleic acids and sequencing (these steps are described below) are carried out correctly. The control species SPC can be a known biological species whose genome is also known, preferably its entire genome is known. The control species SPC can be a natural biological species. It can also be an artificial species, such as RNA (ribonucleic acid) wrapped in a protein coat. Preferably, the control species SPC is not initially present in the sample, or is present in a negligible amount. Preferably, the content of the control substance SPC initially present in the sample, i.e., before addition, is preferably the concentration C of the control species SPC added to the sample. SPC The control species SPC may be, for example, bacteria. It is important to control the concentration of the added control species.
[0060] The following aspects can be considered in selecting control species:
[0061] a) The control species must preferably be different from the organism naturally present or endogenous in the sample, as well as from the expected species of interest: thus, bioinformatic tools will be able to accurately identify sequences generated by sequencing the SPC.
[0062] b) During sequencing, the amount of sequences assigned to the control species must be sufficient to enable correct detection, but not to mask useful information corresponding to the sequences of the biological species of interest. In other words, the control species is preferably detectable by high-throughput sequencing, but is not predominant in the sample. In particular, when a positive (species concentration is above the decision threshold) or negative (species concentration is below the decision threshold) determination is required, the control species is preferably:
[0063] o The size of its genome is preferably similar or at least comparable to the genome size of the biological species of interest. More particularly, the genome size of the control species is 0.1 to 10 times the genome size of the biological species of interest.
[0064] ○C of the control species SPC The concentration can be set according to the judgment threshold. The concentration of the added control species SPC C SPC For example, it may be 0.001 to 1000 times, preferably 0.01 to 100 times, the determination threshold.
[0065] o The nucleic acid of the control species SPC is treated similarly to the nucleic acid of the species of interest during the sample preparation, extraction and sequencing steps, and preferably:
[0066] ■ The percentage of GC (guanine, cytosine) bases is preferably close to the percentage of GC bases of the biological species of interest; by close, it is meant between 75% and 125%, preferably between 80% and 120%.
[0067] ■ The control biological species preferably comprises an intact cell wall or membrane when the biological species of interest is a bacterium, or a protein shell when the biological species of interest is a virus. This condition further allows monitoring of the steps of lysing or extracting nucleic acids of the biological species of interest.
[0068] c) Preferably, the nucleotide sequence of the control species does not contain genomic markers, such as antibiotic resistance markers or virulence markers, so that potential test results for antibiotic sensitivity in the genome of the biological species of interest are not corrupted by the presence of such markers. Preferably, the nucleotide sequence of the control species does not contain any other genes of clinical or industrial significance and are easily detectable.
[0069] d) The control species should preferably be simple and controllable, especially:
[0070] ○ No harm to humans or the environment;
[0071] o and / or resistant to heat treatment, such as freeze drying or freezing, which facilitates storage.
[0072] e) The control species must not sporulate, or can only sporulate minimally.
[0073] f) The control species must have a lysis sensitivity close to that of the biological species of interest.
[0074] g) The control species is provided in the form of pellets, each pellet containing a calibrated concentration of the control biological species in freeze-dried form.
[0075] It should be noted that a single control species SPC can be used, or a plurality of different types of control species can be used. Various control biological species can be used for a given biological species of interest. According to one possibility, the control species forms a calibrant. According to another variant, a calibrant different from the control species is added to the sample. The calibrant allows the concentration of the species of interest to be estimated. This alternative corresponds to a variant of the invention, described after the description of steps 61 to 64. See the section entitled "Variations".
[0076] The concentration of SPC added to the control species C SPC Preferably it is precisely known. In particular, it can allow quantification of the concentration of the biological species of interest in the sample, if certain conditions are met, and the control species then forms the calibrator. The term "added concentration" means the concentration of the control species in the sample resulting from the addition of the control species.
[0077] In the description of steps 30 to 60, the addition of a single type of control species to the sample is described by way of advantageous example. The control species then performs a quality control function in the steps of metagenomic analysis, as well as the function of a calibrator, allowing the concentration of the biological species of interest to be quantified.
[0078] At the end of step 20, a certain concentration C SPC A control species of C will be added to the sample. SPC It can be expressed as GEq / mL (genomic equivalents per milliliter).
[0079] Step 30 : Lysis and extraction of nucleic acids.
[0080] In this step, the cells of the sample, in particular the cells of the biological species of interest and the control species, are lysed in order to extract their DNA. Various strategies can be envisaged:
[0081] ■Lysis can be parameterized to preferentially target biological species of interest;
[0082] ■ The control species must have the same lysis sensitivity as the biological species of interest, or a lysis sensitivity that can be considered equivalent.
[0083] ■ The lysis may include a first lysis aimed at substantially lysing cells other than the species of interest. For example, such a first lysis may be envisaged when the biological species of interest is very rare relative to the cells of the matrix of the sample. After the first lysis, the released nucleic acids are removed and then a second lysis is performed, targeting the biological species of interest. In this case, the control species is preferably resistant to the first lysis,
[0084] and is not resistant to a second lysis.
[0085] After lysis, DNA is extracted from the sample, for example using the extraction method described in WO2014 / 114896.
[0086] The DNA extracted from the sample can be basically composed of the DNA of matrix, namely composed of the DNA of the environment of extracting the sample.In this case, sample can be selectively captured and / or amplified, mainly for the sequence and / or physicochemical modification of the genome of interested biological species.In this case, the control species comprises the sequence and / or physicochemical modification of selective capture or amplification targeting.On the contrary, the sample may experience the consumption basically for the matrix DNA.In this case, the control species does not comprise the sequence or physicochemical modification that may be consumed targeting.
[0087] Step 40 : Amplification and sequencing.
[0088] After DNA is extracted, the DNA fragments are optionally subjected to amplification that can be a targeted type, such as by polymerase chain reaction (PCR), or a non-targeted type, such as by whole genome amplification (WGA). The DNA extracted from the sample is appropriately amplified and sequenced, preferably whole genome sequencing (WGS). There are many sequencing techniques, such as sequencing by synthesis (SBS), or nanopore sequencing, or hybrid sequencing. Regardless of the technology used, the purpose of sequencing is to provide a digital nucleic acid sequence, referred to as a read. Sequencing includes preparing a sequencing library (library preparation), optionally followed by an amplification step, and then the actual sequencing step. Since the technology for sequencing nucleic acids is well known, it will not be described in detail. The MiSeq platform sold by Illumina can be used for amplification and sequencing.
[0089] During the preparation of sequencing libraries, DNA can be randomly scattered to obtain nucleic acid sequences of a target average length, generally between 50 bases and 300 bases. Reference is made to shotgun sequencing or whole genome sequencing (WGS). Using this technology, nucleic acids are treated the same during the preparation of sequencing libraries regardless of their source.
[0090] After the sequencing library is prepared, high-throughput sequencing is performed. The sequencer reads the bases of the sequenced DNA fragments to obtain sequences called reads, each of which corresponds to a sequence decoded by a sequencer. The sequence generated by sequencing is then compared with the genome stored in the database, especially including the genome of the expected biological species of interest and the genome of the control species. Sequencing is an operation known to those skilled in the art. Details related to sequencing operations are given, for example, in documents related to the prior art, particularly in WO2018 / 069430 or the publication of RuppéE cited above.
[0091] The sequencer transmits files corresponding to the measurements performed and containing the reads to a data processing unit. The latter comprises a memory in which are stored instructions allowing the execution of sequencing algorithms. For each sequence, the sequencing algorithms allow the identification of the genome containing this sequence among the multiple genomes stored in a database. They also allow the determination of the position of each sequence in the genome to which it belongs and the assembly of the various sequences belonging to a given genome.
[0092] At the end of step 40, sequencing data related to the various biological species of the sample will be obtained. In particular, it concerns the identification of each species and the amount of sequence assigned to each identified species. In particular, the amount of sequence assigned to the biological species of interest R will be obtained. SOI and the amount of sequences assigned to the control species R SPC .
[0093] Step 45 : Identify the species to which the read belongs.
[0094] In this step implemented by the data processing unit, with respect to bacterial species, the source of each read is identified. This step is generally referred to as binning or classification binning or allocation, including comparing each read with the digital nucleic acid sequence of a reference database. For example, Kraken, (Wood and Salzberg, "Kraken:ultrafast metagenomic sequence classification using exact alignments", Genome Biology, 2014), or "Wowpal Wabbit" (Vervier et al., "Large-scale machine learning for metagenomics sequence classification", Bioinformatics, 2015) or "BWA-MEM" (Li, "Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM", Genomics, 2013) are known binning software packages. Preferably, if the read is fully contained in the genome of the species of interest represented by the database, the read is assigned to the species of interest.
[0095] Step 50 : Normalization
[0096] The amount of sequencing data obtained from step 45 is different for each sample. Specifically, the amount of sequences generated by sequencing depends on the quality and amount of DNA of the various constituent biological species in the sample. Therefore, it is preferred or even necessary to normalize the amount of sequences associated with the species relative to a reference amount. The normalization depends on the type of sample analyzed and the metagenomic analysis applied. For example, the reference amount can be the total number of sequences generated by the analyzed sample. The normalized amount of sequences associated with each species, i.e., the amount divided by the reference amount, is usually multiplied by 1 E 6 to obtain normalized amounts corresponding to reads per million (or RPM).
[0097] According to other variants, non-exhaustive reference quantities may be:
[0098] - Total number of sequences associated with all identified microorganisms;
[0099] - the total number of sequences associated with the organism from which the sample was extracted: for example, when the organism is a human, the total number of sequences associated with the human genome can be determined;
[0100] -The total number of sequences associated with a reference species. A reference species is an endogenous or exogenous species that is assumed to always be present in the various samples collected. A reference species can be a control species.
[0101] - The total number of sequences associated with a predetermined species in a sample not containing the biological species of interest (negative sample) or in a buffer not containing a sample.
[0102] Step 50 is performed for the biological species of interest (or for each biological species of interest) and the reference species (or for each reference species SPC or for each calibrator). Thus, a normalized quantity RN of the biological species of interest SOI (or for each biological species of interest) is obtained. SOI , and obtain the normalized amount RN of the control species SPC (or each control species or each calibrator) SPC In the notation RN, the letter N indicates that the quantity has been normalized.
[0103] In the following, without limitation, only a single biological species of interest and a single control species will be considered.
[0104] In the rest of the description, the term amount may refer to a normalized amount.
[0105] Step 60 :Interpretation.
[0106] This step is an important step of the present invention. It involves determining to what extent the sequencing results are interpretable.
[0107] To this end, the method comprises determining a confidence level attributable to the aforementioned steps, in particular to the aforementioned steps 30 to 50. The confidence level is attributable to the control species, in particular that the control species was introduced prior to step 30.
[0108] This step uses the decision threshold DT SOI and DT SPC , which are respectively associated with the biological species of interest SOI and the control species SPC. The decision threshold can be established based on the statistical decision thresholds determined for the biological species of interest and the control species, respectively. The statistical decision threshold is pre-established in step 100 described below. Typically, the statistical decision threshold corresponds to the lowest value of the analyte concentration measured using the detection method, which is statistically different from the concentration measured when the analyte is not present in the sample under the same conditions. Each decision threshold can be equal to the statistical decision threshold, or determined according to the statistical decision threshold, in particular, k times the statistical decision threshold, k being a non-zero real number.
[0109] Interpretation aims to normalize the number of sequences assigned to the SOI of the biological species of interest and the SPC of the reference species, respectively, by RN SOI and RN SPC Compared with their respective decision thresholds. Specifically, when the normalized amount of the sequence assigned to the biological species of interest is higher than or equal to the decision threshold associated with it, it can be considered that the biological species of interest has been detected with an acceptable confidence level. The same is true for the control species. Based on the comparison, four situations can be distinguished:
[0110] ■RN SOI ≥DT SOI And RN SPC ≥DT SPC : See step 61
[0111] ■RN SOI ≥DT SOI And RN SPC <DT SPC : See step 62
[0112] ■RN SOI <DT SOI And RN SPC ≥DT SPC : See step 63
[0113] ■RN SOI <DT SOI And RN SPC <DT SPC : See step 64
[0114] Step 61 Quantification
[0115] When RN SOI ≥DTSOI And RN SPC ≥DT SPC The confidence level is considered adequate when the detection of the biological species of interest and the control species is confirmed. The SOI of the species of interest is considered to be present in the sample with an adequate confidence level. Its concentration C SOI It can be estimated based on the following factors:
[0116] - Concentration C of the control species SPC added to the sample after step 20 SPC ;
[0117] - the amount R of sequences assigned to the control species SPC obtained from step 45 SPC , which is optionally normalized;
[0118] - the amount of sequences assigned to the biological species of interest (or normalized sequence amount) obtained in step 45;
[0119] - Data related to the genome size of the reference species and the organism of interest.
[0120] For example, you could use the following expression:
[0121]
[0122] in:
[0123] -L SPC and L SOI are the genome lengths of the control species and the biological species of interest, respectively;
[0124] -α is a correction factor determined empirically based on training samples of known concentrations of the biological species of interest. The correction factor α allows for differences in the efficiency of the process of sequencing the biological species of interest and the control species to be taken into account. By default α can be set equal to 1 (α=1). This unit value allows for sufficiently good absolute quantification to be obtained in order to determine whether a sample is positive or negative relative to the decision threshold. When the added concentration is expressed in GEq / mL, the concentration of the biological species of interest is also expressed in the same unit. Alternatively, sequencing includes assembling sequences associated with the control species and the biological species of interest, respectively, and determining the coverage Cov of the assembly for each species. The concentration C of the biological species of interest can then be calculated using the following equation: SOI :
[0125]
[0126] in:
[0127] -Cov SPC and Cov SOIare the coverages determined for the reference species and the species of interest, respectively. Coverage represents the average number of bases sequenced at a given position in the genome, as described in the publication “Le “High-throughput sequencing in clinical practice”, Archives de Pédiatrie 2017, 24, 373-383.
[0128] -α' is a correction factor determined empirically based on training samples of the biological species of interest with known concentrations. The correction factor α' allows differences in the efficiency of sequencing the biological species of interest and the control species to be taken into account. By default α' can be set equal to 1 (α'=1). This unit value allows obtaining sufficiently good absolute quantification in order to determine whether a sample is positive or negative relative to the decision threshold.
[0129] According to a variant described below, step 61 can be implemented with a biological species that is different from the control species and forms a calibrant. In this case, the control species is used in step 60 to confirm the detection of the biological species of interest, while step 61, the quantification step, is implemented using a calibrant, which is used only for quantification. Preferably, the properties of the calibrant are similar to those of the control species and correspond to the properties described in step 20. Quantification using a calibrant can be performed using expression (1) or expression (1'). Expression (1) becomes:
[0130]
[0131] in:
[0132] -R CAL is the sequence number assigned to the calibrator, preferably normalized;
[0133] -L CAL is the length of the calibrator genome;
[0134] -C CAL is the concentration of the calibrant added to the sample;
[0135] -α is a correction factor as described in reference (1).
[0136] Expression (1') becomes:
[0137]
[0138] -Cov CAL is the coverage determined for the calibrant;
[0139] -α' is the correction factor as described in reference (1').
[0140] According to one embodiment, no control species is used. According to this embodiment, a calibrator is used and the concentration of the biological species of interest is achieved based on the amount of preferably normalized sequences.
[0141] Step 62:
[0142] When RN SOI ≥DT SOI and RN SPC <DT SPC it means that the control species is considered not detected while the biological species of interest is considered detected. However, the biological species of interest cannot be quantified with sufficient confidence. The confidence level is considered insufficient. This step involves comparing the added concentration C SPC of the control species and a determination threshold SD such that:
[0143] - If C SPC <SD, no information about the concentration of the target biological species relative to the determination threshold is obtained;
[0144] - If CSPC ≥ SD, the concentration of the biological species of interest cannot be estimated, but it can be considered higher than the determination threshold. Although the concentration of the biological species of interest cannot be quantified, it can be concluded that the determination threshold has been exceeded.
[0145] Step 63:
[0146] When RN SOI <DT SOI and RN SPC ≥DT SPC it can be considered that the sequencing is working properly. The confidence level is considered sufficient. This step involves estimating the minimum detectable concentration of the biological species of interest. The minimum detectable concentration Cmin SOI of the biological species of interest corresponds to the lowest concentration that can be distinguished from the background noise. It is genomic equivalent to the concentration corresponding to the determination threshold DT SOI of the biological species of interest. The minimum detectable concentration can be determined based on the following factors:
[0147] - The concentration C SPC of the control species SPC added to the sample after step 20;
[0148] - The amount of sequences R SPC assigned to the control species SPC obtained in step 45;
[0149] - The determination threshold DT SOI associated with the biological species of interest;
[0150] - Data related to the genome size of the reference species and the organism of interest.
[0151]
[0152] in:
[0153] -L SPC and L SOI are the genome lengths of the control species SPC and the organism species of interest SOI, respectively;
[0154] -α is the correction factor described with reference to equation (1).
[0155] Step 63 includes comparing the determination threshold SD with the minimum detection concentration Cmin SOI Compare so that:
[0156] - If Cmin SOI ≤SD, the detection of the biological species of interest can be considered negative: the concentration of the biological species of interest in the sample is lower than or equal to the decision threshold;
[0157] - If Cmin SOI >SD, it provides no information on the presence or absence of the biological species of interest in the sample and its concentration relative to the decision threshold.
[0158] Step 64:
[0159] When RN SOI <DT SOI And RN SPC <DT SPC When the control species SPC is not detected, it indicates that the assay does not have the performance required to detect the biological species of interest. The confidence level is considered insufficient. The assay cannot be interpreted. The assay may be considered invalid. This situation may occur in the following situations:
[0160] - When one of the sequencing steps does not achieve the performance required to detect the target biological species;
[0161] - and / or when the sample contains a large amount of DNA from the patient or matrix or microbial flora;
[0162] - and / or when the sample contains at least one substance which has a high concentration and produces a large number of sequences, which has the effect of masking other sequences of interest.
[0163] At the conclusion of one of steps 61 to 64, the presence of the biological species of interest at a concentration above the decision threshold and its quantification, if any, is confirmed to aid in diagnosis.
[0164] Deformation
[0165] In the above described embodiment scheme, the control species SPC performs the function of controlling the quality of the metagenomic analysis and the function of a calibrator, thereby allowing the quantification of the biological species of interest in the sample.
[0166] According to a variation, a control species SPC and a calibrator different from the control species are added to the sample. For example, it involves two different bacterial species. The control species SPC performs a function related to controlling the quality of the metagenomic analysis. The calibrator allows the quantification of the biological species of interest in the sample according to formula (1) or (1') or (2). When the calibrator is different from the control species, the calibrator preferably has the same properties as the control species, which are described with reference to step 20. The control species SPC is added at a first concentration. A decision threshold is assigned to it, and step 60 is implemented by comparing the normalized amount of the sequence assigned to the control species generated by step 50 with the decision threshold associated with the control species. The calibrator is also added to the sample at a second concentration. A decision threshold is assigned to it. In step 61, the normalized sequence amount associated with the calibrator and the decision threshold associated with it can be considered to perform quantification.
[0167] Calibrators can be added before lysis, or after lysis and before sequencing.
[0168] In another variation, multiple calibrators are added to the sample, each calibrator being selected for one or more species of interest. In particular, bacterial populations may have significantly different responses to the process of extracting nucleic acids (e.g., Gram+ bacteria and Gram- bacteria). Advantageously, calibrators consisting of Gram+ bacteria are added when one or more species of interest are Gram+, and calibrators consisting of Gram- are added when one or more species of interest are Gram-. Similarly, the species of interest may consist of bacteria and viruses. In this case, the first calibrator is a bacterium, the second calibrator is a virus, and the auxiliary calibrator is a virus. Typically, this involves selecting a calibrator that performs sample preparation steps (extraction, optional sequence library preparation or amplification and sequencing) in the same manner as possible with the species of interest that it calibrates.
[0169] Step 100: Establish a decision threshold.
[0170] As mentioned above, control species and interested biological species need to be associated with decision threshold respectively.For given biological species (control biological species or interested biological species), before explaining the result, use the training sample that does not comprise described kind to establish decision threshold.These samples are negative with respect to expected species.These samples are the representative of analysis sample.Representativeness refers to that these training samples all comprise the biological species population that is suitable with the biological species population of analysis sample no matter from qualitative angle or from quantitative angle.Can use the method based on standard culture and / or PCR to verify that there is not interested biological species and / or control species in each test sample.
[0171] Each training sample is sequenced, preferably under the same conditions as described in steps 30 to 45. After sequencing, the amount of sequence assigned to the expected species is determined. As described in step 50, this amount is preferably normalized.
[0172] Therefore, the decision thresholds associated with the biological species of interest and the control species, respectively, can be established using a first training sample that does not include the biological species of interest and a second training sample that does not include the control species, respectively. The first training sample can be the second training sample, and vice versa, in which case the decision thresholds associated with the biological species of interest and the control species are determined by the same training sample.
[0173] Sequencing is preferably performed on a statistically representative amount of training samples. Thus, a statistical distribution of normalized amounts of sequences is obtained. Next, the mean μ and a dispersion indicator, such as the standard deviation σ or variance σ, of the distribution are estimated. 2 The decision threshold is estimated by adding n times the discrete index to the mean value μ, where n is a real number, usually 2 to 4.
[0174] Since the decision thresholds associated with the biological species of interest and the control species, respectively, are intended to be compared to normalized quantities of sequences of the biological species of interest and the control species, it is important to perform a normalization in step 100 similar to that performed in step 50 .
[0175] The above steps can target multiple biological species of interest at the same time. This is also an additional significant advantage of metagenomic analysis, which allows multiple biological species to be processed simultaneously. Another advantage of metagenomic analysis is the ability to use multiple control species at the same time. Therefore, one control species can be used to target one or more than one biological species, while other control species can be used to target other biological species of interest. This is another advantage of metagenomic analysis.
[0176] It is even conceivable to use multiple control species for a given biological species of interest. For example, for a given biological species of interest, multiple control species can be used to implement steps 61 to 64. This makes it possible to reduce the risk of method failure due to sequencing problems with the control species. For different [biological species, control species] pairs, an estimate of the presence of the biological species of interest relative to the decision threshold is obtained. When multiple control species are used for a given biological species of interest, multiple quantifications can be obtained according to equations (1), (1'), in which case the average or median of the quantifications obtained can be considered, or it can be considered to be the most unfavorable quantification, that is, resulting in the highest concentration of the biological species of interest, or more generally resulting in a concentration closest to the decision threshold.
[0177] More generally, metagenomic analysis still requires powerful computational means. As a compensation, it allows a certain degree of operational flexibility, since it allows the simultaneous processing of multiple biological species (and / or multiple reference species), the only condition being that the genome of the desired biological species and the genome of the respective reference species are known.
[0178] Steps 61 to 64 are implemented by a computing unit, such as a microprocessor, based on the sequencing data generated in steps 40, 45 and 50 and delivered by the processing unit. The sequencing data corresponding to the measurement data obtained from the analyzed sample are thus transmitted to the computing unit via a wired or wireless link so that one of the steps 61 to 64 can be executed. The microprocessor is connected to a memory containing instructions allowing the execution of steps 61 to 64.
[0179] Example 1
[0180] In the first example, Bacillus subtilis was demonstrated to be a good candidate for use as a control species in metagenomic sequencing of samples generated from bronchoalveolar lavage (BAL) performed on human patients. Since the patients are human, it is expected that such samples will contain a large amount of human DNA.
[0181] Metagenomic sequencing of such samples may help diagnose hospital-acquired pneumonia for diagnostic purposes. The clinical decision threshold was set at 1.0E4 CFU / mL, where CFU is the acronym for colony-forming units.
[0182] In order to remove the patient's DNA, the analysis protocol includes a preliminary lysis, in which the patient's DNA is removed. In the first lysis, the sample is treated with a lysis agent that specifically targets the patient's cells. Such lysis agents are described, for example, in WO2014 / 114896. The released DNA is then removed by enzymatic action and washing. The sample then undergoes a second mechanical and chemical lysis to extract bacterial DNA.
[0183] Prior to the lysis step, the protocol provides for the addition of a control species to the sample. The biological species forming the control species must be resistant to lysis of human cells and at the same time sensitive to lysis of bacterial cells. Now, it is known that some bacteria, especially Gram-positive bacteria, are difficult to lyse. Therefore, a biological species with a lysis resistance comparable to that of Gram-positive bacteria is selected as the control species.
[0184] In addition, metagenomic sequencing was performed with the goal of detecting and potentially quantifying approximately 20 biological species of interest, each of which is a bacterium included in the following list: Acinetobacterbaumannii, Citrobacter freundii, Citrobacterkoseri, Enterobacter aerogenes, Enterobacter cloacae, Escherichia coli, Haemophilus influenzae, Hafnia alvei, Klebsiella oxytoca, Klebsiella pneumoniae, Legionella pneumophila, Morganellamorganii, Proteus mirabilis, Proteus vulgaris, Providencia stuartii), Pseudomonas aeruginosa, Serratia marcescens, Staphylococcus aureus, Stenotrophomonas maltophilia, Streptococcus pneumoniae.
[0185] The control species SPC must also be able to be sequenced with an efficiency comparable to the species of interest listed above. It is well known that sequencing efficiency depends primarily on the size and GC (guanine-cytosine) content of the genome. Therefore, in this embodiment, the genome size of the control species must be between 1.9 and 6.6 megabases, and the GC content must be between 33% and 66%. In addition, the concentration of the control species added to the sample is set to 1.0E4 CFU / mL, a concentration comparable to the above-mentioned judgment threshold.
[0186] The inventors evaluated the desirability of using the following species as control species: Bacillus stearothermophilus, Synechocystis sp. PCC6803, Pelagibacter ubique, Methanocaldococcus jannaschii, Aeropyrum pernix, Kocuria rhizophila, Azospirillum lipoferum, Lactococcus lactis, Synechococcus sp. WH 7805, Schizosaccharomyces pombe, Pantoea stewartii, Phage T4, Pichia pastoris, Armored DNA Quant TM and Bacillus subtilis.
[0187] Among these different species, the results show that Bacillus subtilis has the characteristics required for use as a control species. The Bacillus subtilis genome size is 4.12Mb (megabases) and the GC content is 43.6%. In addition, Bacillus subtilis is commercially available in the form of "BioBalls" (registered trademark)-manufacturer Biomérieux. These BioBalls are water-soluble balls containing calibrated concentrations of Bacillus subtilis, which can adjust the concentration of the added control species. Rehydration of the BioBall MultiShot 550 in a 600 μL bronchoalveolar lavage fluid sample, which is equivalent to an added concentration of Bacillus subtilis equal to 9.2E3 CFU / mL, close to the judgment threshold of 1.0E4 CFU / mL.
[0188] DNA extracts from samples containing fresh cultures of Bacillus subtilis and from samples containing Bacillus subtilis added in the form of BioBalls were also compared by real-time PCR. The results of the PCR were comparable.
[0189] Seven samples obtained by bronchoalveolar lavage (BAL) without prior addition of Bacillus subtilis were sequenced. In four of the seven samples, a negligible amount of sequences assigned to Bacillus subtilis was observed: less than 5 reads per million. Therefore, the amount of false positives is negligible. In the other samples, sequences were assigned to Bacillus subtilis, either due to an error in the sequence assignment software or due to the presence of sequences in the samples that are very similar to Bacillus subtilis. However, the amount of sequences assigned to Bacillus subtilis never exceeded 200 reads per million: it is therefore relatively low.
[0190] The uncertainty range was similar for the 46 samples obtained by BAL spiked with Bacillus subtilis at a concentration of 1.7E4 CFU / mL. After sequencing, the amount of sequence assigned to Bacillus subtilis exceeded 1000 reads per million for 36 of the 46 samples.
[0191] This example demonstrates that Bacillus subtilis is a biological species that can easily form a control species in samples obtained by BAL, using the analytical protocol described at the beginning of the example.
[0192] Example 2
[0193] This example describes the detection and quantification of S. aureus in samples obtained by bronchoalveolar lavage (BAL) by applying the double lysis protocol described in Example 1 and steps 10 to 50 above.
[0194] A set of 13 samples obtained by BAL was used. Based on the conclusions of Example 1, the control species used was Bacillus subtilis, which was added to each sample at a concentration close to the decision threshold (1.0E4 CFU / mL). In this example, the control species was prepared by rehydrating the BioBall MultiShot 10 in 1.1 mL of PBS buffer (PBS stands for phosphate buffered saline). E 8-Bacillus subtilis ATCC 19659 (Biomérieux). The control species was diluted to 1.0E6 CFU / mL in PBS and 10 μL was added to 600 μL of sample. Thus, an added concentration of 1.7E4 CFU / mL of the control species was obtained.
[0195] Each sample was processed for a maximum of 48 hours after sampling. As described above, each sample underwent a first lysis specific for human cells. The unlysed cells were precipitated and treated in DNase I. Before extracting human DNA, DNase was inactivated by heating and adding EDTA (ethylenediaminetetraacetic acid). Each sample was then subjected to a second lysis by adding the sample to a bead beating tube containing a mixture of glass beads with a diameter of 1 mm and Zr / Si beads with a diameter of 0.1 mm. The lysate was obtained by shaking the tube for 20 minutes. DNA was extracted from the lysate using the Biomérieux platform easyMAG (registered trademark). The elution volume was 25 μL. The extract was stored at -20°C.
[0196] A sequencing library of 2×250 paired-end reads was prepared using the Nextera (registered trademark) XT DNA Library Preparation Kit (manufacturer Illumina). The samples were sequenced using the MiSeq (registered trademark) platform with the “MiSeq Kit V3” (Illumina).
[0197] The sequences were processed using the software package KRAKEN V0 10.5b and the processing unit of the internal sequence database. The database contains in particular the sequence of the human genome and the sequences of the 20 species of interest listed in Example 1. The amount of sequences generated in each sample ranged from 331,000 to 17,000,000. The number of sequences associated with the control species (Bacillus subtilis) and the species of interest (Staphylococcus aureus) was normalized to reads per million (RPM).
[0198] In addition, a quantitative reference measurement was performed for each sample by quantitative PCR (qPCR) targeting the SpA gene. Amplification and real-time readout of the fluorescent signal were performed on the platform CFX96 Touch Real-Time PCR Detection System (Biorad).
[0199] Table 1 summarizes the sequencing results of 13 culture-positive samples. Columns 1 to 7 correspond to:
[0200] - reference samples;
[0201] - Quantification of Staphylococcus aureus by culture;
[0202] - Quantification of Staphylococcus aureus by qPCR;
[0203] - Normalized quantity RN assigned to the sequence of the control species (Bacillus subtilis) SPC ;
[0204] - Normalized quantity RN of the sequence assigned to the biological species of interest (Staphylococcus aureus) SOI ;
[0205] - Where possible, the concentration C of the biological species of interest determined using equation (1) SOI Performing quantification, which is described in step 61;
[0206] - Where possible, the concentration C of the biological species of interest determined using formula (1') SOI Quantification is performed, which is described in step 61.
[0207] In this example, the control species SPC acts as a calibrator, in the sense that it is used in the quantification step.
[0208] SOI NA and SPC NA indicate that the amount of sequence associated with the biological species of interest SOI and the control species SPC, respectively, is insufficient for assembly. NA is an acronym for Not Assembled.
[0209]
[0210] Table 1
[0211] Samples 1, 2, 3, 4, 5, 6, 7, 9, 10, 11, 12 and 13 (i.e., 12 samples out of 13 samples) correspond to the configuration described in step 61, in which the species of interest can be quantified, for example, according to formula (1) and formula (1').
[0212] Sample 8 corresponds to the configuration described in step 64: the result is not interpretable. Additional investigations revealed that for this sample, the sequence demultiplexing step failed. This particular case is interesting because it shows that considering a control species can avoid generating "false negatives".
[0213] For the “quantifiable” samples (1, 2, 3, 4, 5, 6, 7, 9, 10, 11, 12, and 13), the concentration C SOI Estimated using equation (1'). However, sequences associated with the control species SPC or with the biological species SOI of interest are sometimes not assembled; in this case, the biological species of interest cannot be quantified using this scheme, which uses equation (1). This is particularly the case with samples 2 and 13, where the amount of sequence associated with the biological species of interest is insufficient to obtain an assembly and measure sequencing depth. Therefore, quantification based on equation (1') can only be envisaged when the amount of sequence is sufficient. Quantification based on equation (1) may be preferred.
[0214] Figure 2A A comparison of quantification of Staphylococcus aureus by culture (x-axis) and sequencing (y-axis) is shown. The correlation coefficient is low (r 2=0.2929). This low value can be explained by the imprecision of the culture method and the difference between the amount of viable and culturable cells detected by culture and the total number of genomes detected by sequencing. Some of the patients from whom the samples were extracted were receiving antibiotic treatment, which tends to reduce the proportion of viable and culturable bacteria relative to the total number of bacteria. Therefore, culture only allows to obtain partial quantitative information.
[0215] Figure 2B The correlation between the quantitative results of macrosequencing (formula (1) - y axis) and quantitative PCR (x axis) is shown. The correlation coefficient is higher: r 2 =0.9906, which proves the reliability of meta-sequencing quantification.
[0216] Example 3
[0217] In this example, the detection of 20 pathogenic bacteria of interest listed in Example 1 in samples obtained by bronchoalveolar lavage (BAL) or mini-bronchoalveolar lavage (mini-BAL) was tested. The control species SPC (Bacillus subtilis) was obtained in the same manner as in Example 2 and added to each sample at a concentration of 1.7E4 CFU / mL. The judgment threshold for BAL samples was 1.0E4 CFU / mL, and the judgment threshold for mini-BAL samples was 1.0E3 CFU / mL.
[0218] Two sets of samples were collected: a training set, including 46 samples (23 BAL samples and 23 mini-BAL samples), and an analysis set, including 40 samples (33 BAL samples and 7 mini-BAL samples).
[0219] For all samples in both the training and analysis sets, culture reference measurements were performed for each species of interest.
[0220] The samples were subjected to two cleavages as described in Example 2. Sequencing was performed as described in Example 2.
[0221] For each species of interest and control species, the amount of sequence is normalized to the number of reads per million reads (RPMb) associated with the bacterial species, see step 50 .
[0222] For each biological species of interest, the decision threshold DT SOI Only training samples were considered for determination, where the biological species of interest were considered undetected. The species of interest was considered undetected in the sample when the microbial culture result of the sample was negative for the detection result of the SOI involved and the detection result of the MetaPhlAn marker sequence specific to the SOI involved was negative. Figure 3The statistical distribution of the normalized sequence quantity in the training samples that are negative for the species of interest is shown. The x-axis corresponds to each species of interest, while the y-axis corresponds to the normalized quantity of sequences associated with the species of interest. For each species, the median (the line contained in the box) and the 25th and 75th percentiles (the range of the box) are determined, which allows to obtain a depiction in the form of a box and whisker diagram (or box plot). The ends of each vertical line correspond to the 1st and 99th percentiles. It can be seen that the distributions vary greatly relative to each other, which proves the use of a decision threshold DT for each biological species of interest. SOI For each species of interest, the decision threshold DT is determined according to the above step 100. SOI If μ SOI specifies the mean of the normalized number of sequences assigned to the species of interest, and σ SOI is their standard deviation, then the decision threshold DT SOI Located "3-sigma" above the mean, according to the expression:
[0223] DT SOI =μ SOI +3σ SOI (3)
[0224] The decision threshold DT related to Bacillus subtilis was defined SPC =DTB 枯草芽孢杆菌 Seven training samples without the addition of Bacillus subtilis were considered. The mean value μ of the normalized number of sequences assigned to Bacillus subtilis was determined 枯草芽孢杆菌 , and their standard deviations σ 枯草芽孢杆菌 . Determination threshold DTB 枯草芽孢杆菌 for:
[0225] DT 枯草芽孢杆菌 =μ 枯草芽孢杆菌 +3σ 枯草芽孢杆菌 (3)
[0226] The decision threshold (SD) called the metagenomic threshold is defined to distinguish the normal presence of the bacteria of interest from the infection of the patient by the bacteria of interest. To this end, the microbial culture results of the training set samples were divided into 2 different groups:
[0227] - The "infectious" population, which corresponds to 20 events detected by culture at concentrations equal to or above the clinical threshold, i.e. 1.0E3 CFU / mL for mini-BAL samples and 1.0E4 CFU / mL for BAL samples.
[0228] - The “colonized” population corresponds to 900 events with either uncultured or culture-detected concentrations below the clinical threshold, i.e., 1.0E3 CFU / mL for mini-BAL samples and 1.0E4 CFU / mL for BAL samples.
[0229] In the first two segments, 920 events correspond to the analysis of 46 training samples by microculture, which was performed for each of the 20 biological species of interest.
[0230] Figure 4 Quantification of biological species by culture (x-axis) and metagenomic analysis (y-axis) for various samples is shown. Figure 4 In the figure, black circles correspond to species selected from the group consisting of Acinetobacter baumannii, Citrobacter freundii, Citrobacter kluyveri, Bacillus aerogenes, Enterobacter cloacae, Escherichia coli, Haemophilus influenzae, Hafnia alvei, Klebsiella oxytoca, Klebsiella pneumoniae, Legionella pneumophila, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Pluvedenella stuartii, Pseudomonas aeruginosa, Serratia marcescens, Stenotrophomonas maltophilia, and Streptococcus pneumoniae. White triangles correspond to Staphylococcus aureus.
[0231] Although as in Example 2 ( Figure 2A ), it is sometimes not possible to accurately correlate the CFU / mL concentration obtained from culture with the GEq / mL concentration obtained from meta-sequencing, but Figure 4 It was shown that for a species or a group of species of interest, “colonized” and “infected” populations can still be distinguished based on the results of sequencing quantification (genomic equivalents (GEq)). The metagenomic threshold (SD) was defined taking into account the first half percentile of the concentrations measured in the “infected” population; the value thus obtained was 5.5 E 3GEq / mL.
[0232] Therefore, based on the training samples, a metagenomic threshold can be defined, which forms a decision threshold SD, allowing the separation of samples with a concentration of the biological species of interest above or below a critical value. The critical value can correspond in particular to the above-mentioned decision threshold SD. The concentration of the species of interest determined by sequencing is then compared with the decision threshold associated therewith. It should be noted that the decision threshold generally depends on the biological species involved. Therefore, a decision threshold can be established for a biological species or a group of biological species involved. Two different biological species can be associated with two different decision thresholds.
[0233] 40 samples of the analysis group were sequenced. Tables 2A to 2C summarize the results obtained, each table summarizing the results of samples 1 to 13, 14 to 27 and 28 to 40 respectively. The first row of each table contains the reference number of each sample. The second row indicates the relative decision threshold DT associated with it. SPCControl species SPC detected (+) or not detected (-): see step 60.
[0234] In samples 3, 7, 23 and 35, the control species SPC (RN SPC <DT SPC ). When the species of interest is not detected (RN SOI <DT SOI ), see step 64, the result is not interpretable, which corresponds to code INV. Because the minimum detection concentration is too high, it is not possible to determine the concentration of the species of interest relative to the decision threshold, which in this embodiment is the clinical threshold. When the species of interest is detected (RN SOI ≥DT SOI ), see step 62, because the concentration of the added control biological species is higher than the metagenomic threshold (SM), i.e., 5.5 E 3 GEq / mL, so the detection value of SOI of the species of interest is considered positive above the judgment threshold, which is the clinical threshold in this embodiment. The results correspond to Tables 2A, 2B and 2C:
[0235] - When the biological species of interest detected by microbiological culture is also above the clinical threshold, it is a true positive (TP);
[0236] - A false positive (FP or FP+) is when the organism of interest is not detected above the clinical threshold by microbiological culture.
[0237] In samples 1, 2, 4 to 7, 8 to 22, 24 to 34, and 36 to 40, the control biological species (RN SPC ≥DT SPC ). When the species of interest is not detected (RN SOI <DT SOI ), see step 63, use formula (2) to establish the minimum detection concentration Cmin SOI When the minimum detection concentration Cmin SOI Above the decision threshold SD, these results are not interpretable, which corresponds to the code INV in Tables 2A, 2B, and 2C. SOI When the value is lower than or equal to the decision threshold (metagenome threshold) SD, the detection value of the biological species of interest is considered to be lower than the clinical threshold. The results correspond to Tables 2A, 2B and 2C:
[0238] - A false negative (FN) occurs when the organism of interest is detected above the clinical threshold by microbial culture but quantified below the decision threshold by metagenomic analysis.
[0239] - True negative (empty box) when the organism of interest is not detected above the clinical threshold by microbial culture and metagenomic analysis.
[0240] When the control biological species (RN SPC ≥DT SPC ), and the target biological species (RN SOI ≥DT SOI ), using the formula (1) described in step 61, the concentration C of the biological species of interest is determined using the sequence number associated with the target biological species as a calibrant. SOI These results correspond to Tables 2A, 2B, and 2C:
[0241] -True positive (TP) when the biological species of interest is detected above the clinical threshold by microbiological culture;
[0242] - A false positive (FP or FP+) occurs when the organism of interest is not detected above the clinical threshold by microbiological culture.
[0243] sample 1 2 3 4 5 6 7 8 9 10 11 12 13 SPC + + - + + + - + + + + + + Acinetobacter baumannii INV INV INV Citrobacter freundii INV INV Citrobacter kohlii INV INV INV Aerobacterium INV INV INV INV INV Enterobacter cloacae INV INV INV INV INV INV INV INV INV INV INV INV INV Escherichia coli INV INV INV INV INV Haemophilus influenzae INV INV INV INV Hafnia alvei INV INV Klebsiella oxytoca INV INV INV Klebsiella pneumoniae INV INV INV INV INV Legionella pneumophila INV INV Morganella morganii INV INV Proteus mirabilis INV INV Proteus vulgaris INV INV INV INV INV INV INV Pruvidonella stuartii INV INV Pseudomonas aeruginosa TP FP INV Serratia marcescens INV FP+ FP+ Staphylococcus aureus INV INV INV INV INV TP Stenotrophomonas maltophilia INV INV INV Streptococcus pneumoniae TP INV INV INV INV INV TP
[0244] Table 2A
[0245] sample 14 15 16 17 18 19 20 21 22 23 24 25 26 SPC + + + + + + + + + - + + + Acinetobacter baumannii INV INV Citrobacter freundii INV Citrobacter kohlii INV INV Aerobacterium INV INV Enterobacter cloacae INV INV INV INV INV INV INV INV INV INV INV INV INV Escherichia coli INV INV INV Haemophilus influenzae INV INV Hafnia alvei INV Klebsiella oxytoca INV INV Klebsiella pneumoniae INV INV Legionella pneumophila INV Morganella morganii INV INV Proteus mirabilis INV Proteus vulgaris INV INV INV INV Pruvidonella stuartii INV INV Pseudomonas aeruginosa TP INV TP Serratia marcescens INV Staphylococcus aureus INV INV Stenotrophomonas maltophilia TP INV Streptococcus pneumoniae FP INV INV
[0246] Table 2B
[0247] 27 28 29 30 31 32 33 34 35 36 37 38 39 40 SPC + + + + + + + + - + + + + + Acinetobacter baumannii INV INV INV INV Citrobacter freundii FP INV Citrobacter kohlii INV INV INV Aerobacterium INV FP+ INV INV Enterobacter cloacae INV INV INV INV INV INV INV INV INV INV INV INV INV Escherichia coli INV INV INV INV INV INV Haemophilus influenzae INV INV TP INV INV Hafnia alvei FP INV Klebsiella oxytoca FP FP INV INV Klebsiella pneumoniae FP+ INV INV INV INV Legionella pneumophila INV Morganella morganii INV INV INV Proteus mirabilis INV Proteus vulgaris INV INV INV INV INV INV Pruvidonella stuartii INV INV Pseudomonas aeruginosa INV INV TP TP FP Serratia marcescens FP FP FP INV Staphylococcus aureus INV INV FP+ INV INV INV INV INV INV Stenotrophomonas maltophilia INV INV INV INV INV FP INV Streptococcus pneumoniae INV INV INV INV INV INV
[0248] Table 2C
[0249] Microbiological culture analysis allowed the detection of E 4 CFU / mL, mini-BAL samples are 1 E 3 CFU / mL). Metagenomic analysis allowed the detection of 10 of these events, which corresponds to the notation TP (true positive) in Tables 2A to 2C. The events not detected by metagenomics correspond to E. cloacae in sample 27 and can be explained by the high abundance of sequences associated with E. cloacae in samples where E. cloacae was not present (see Figure 3 ), which results in a very high decision threshold, which results in a minimum detection concentration Cmin SOI Frequently above the metagenomic threshold (SM). Metagenomic testing considers this result invalid, see INV in Table 2C.
[0250] Metagenomic analysis allowed the detection of an additional 19 events relative to microbial culture. These events are designated as FP (false positive) or FP+ in Tables 2A to 2C. Five FP+ events correspond to detections in which MetaPhlAn markers and BLAST alignments (BLAST is an acronym for Basic Local Alignment Search Tool) allowed confirmation of the presence of the species of interest in the sample, although it was not detected by culture. These complementary events may be due to the higher sensitivity of metagenomic tests relative to microbial culture detection, which only allows the detection of the viable and culturable part of the microbiome. FP events correspond to false positives in which the number of reads associated with the species of interest was too low to be confirmed by searching for MetaPhlAn markers and BLAST alignments. These complementary events may also be due to the higher sensitivity of metagenomic tests relative to detection by microbial culture; however, due to the lack of confirmation, the lack of specificity of metagenomic tests cannot be ruled out.
[0251] Metagenomic testing produced 185 invalid results – INV in Tables 2A, 2B, and 2C. These results correspond to the failure to detect the species of interest SOI but cannot be explained because the minimum detectable concentration Cmin SOI above the metagenomic threshold (SM). This result is particularly different from that of microbiological culture, which often gives negative results if the detection sensitivity of the bacterial species in the test sample is not individually validated using some equipment. Validation using metagenomic testing can limit the risk of false negatives, which is clearly illustrated by the fact that Enterobacter cloacae was not detected in sample 27.
[0252] Comparison of the results of BAL and mini-BAL samples from patients infected with the pathogen of interest is shown in Table 3, which clearly shows the advantage of using the control species described in the present invention. Detecting pathogens above the clinical decision threshold directly based on the normalized read counts assigned to the species of interest produced almost a 9-fold increase in false positive results. The use of control species can significantly improve the specificity of metagenomic testing and better detect infection without sacrificing sensitivity.
[0253]
[0254] Table 3
[0255] The invention is described for a particular application to so-called shotgun sequences. The invention is also applicable to targeted sequences, such as so-called 16S sequences. In this case, before sequencing, a step of amplifying the target gene is performed to increase its copies in the sample. The reads used by the invention are then reads corresponding only to the target gene.
[0256] The use of Bacillus subtilis as a control species in metagenomic analysis of BAL or mini-BAL samples is described. As a variant, another control species can be used, as long as it meets all or part of the criteria described in step 20. For example, it may be a species selected from the following: Bacillus stearothermophilus, Synechocystis sp. PCC6803, Pelagibacterium ubiquitum, Methanococcus jannaschii, Aerothermobacterium agile, Coxiella rhizophila, Azospirillum lipogenicum, Lactococcus lactis, Synechococcus sp. WH 7805, Schizosaccharomyces pombe, Pantoea stutzeri, Bacteriophage T4, Pichia pastoris, Armored DNA Quant TM and Bacillus subtilis.
[0257] A variety of control species are described that take the form of elements comprising nucleic acids contained or encapsulated in a membrane (bacterial membrane, capsid, etc.). This feature is used to verify the function of consistency of the metagenomic analysis, in particular to determine whether the process of extracting nucleic acids works as expected. Obviously, when the biological species is used only as a calibrator, that is, the function of verifying consistency is not allowed and only the quantitative function is performed, the calibrator can consist of a known amount of free nucleic acid added to the sample or to the DNA extract.
[0258] The addition of the control species and the calibrator is described simultaneously, i.e. before the step of extracting the nucleic acid sequence. When two different biological species are used to perform the functions of consistency verification and quantification (calibrator), respectively, the calibrator can be added in a subsequent step, preferably after the step of lysing the sample, especially when the calibrator is a naked nucleic acid, so as not to damage the latter.
[0259] The method according to the invention allows in particular the analysis of biological species of interest in a sample.Preferably, in the case of clinical applications, the method according to the invention is accomplished by the following steps: determining an antibiotic therapy according to the species identified and analyzed in the sample, and administering the determined antibiotic therapy to the patient.
[0260] The method allows to help diagnose whether a sample is contaminated with a species of interest, which may be bacteria or fungi. This allows to define the appropriate treatment (antibiotic treatment in the case of bacteria, antifungal treatment in the case of yeast or fungi) based on the identification of the species of interest and any signs of antimicrobial resistance detected in the genome.
[0261] More generally, depending on the target application, when the concentration of a biological species is above a determination threshold, this can be considered as an indication of an abnormal occurrence. Appropriate remedial measures are determined to remedy the abnormality. For example, in the field of food processing, the species of interest may be bacteria. When the concentration exceeds a certain threshold, the remedial measures may be to remove or destroy the food intended for sale, and / or to clean the production facilities. This also applies when it comes to sanitary inspections, such as sanitary inspections of a part of a facility such as a hospital to prevent nosocomial infections. The presence of recognized undesirable biological species causes remedial measures to be taken, such as cleaning or decontamination.
[0262] The invention will be implemented in the health field to assist diagnosis, or more generally, in fields involving the analysis of samples extracted from the environment or industrial processes, such as in the food processing industry, the pharmaceutical industry or in the cosmetics industry. It can also be used for hygiene inspections.
Claims
1. A method for detecting a microorganism of interest (SOI) potentially present in an analytical sample, the sample having been previously obtained from an organism or from an industrial process or extracted from the environment, the microorganism of interest having a known or partially known genome, the analytical sample comprising a mixture of a plurality of microorganisms, the method The following steps are involved: a) extracting nucleic acid from the analysis sample; b) sequencing the nucleotide sequence extracted in step a); c) Based on sequencing results: (i) assigning the sequence generated in step b) based on a sequence reference database; (ii) Determine the number of sequences assigned to the microorganism of interest (R SOI , R.N. SOI ); The method is characterized in that it comprises adding a calibrant to the analysis sample before step a), wherein the calibrant is a calibrant with a known concentration (C CAL ) added microorganisms, the calibrator having a known genome, and step c) comprising: (iii) determining the sequence quantity (R) assigned to the calibrator CAL ); d) according to the sequence quantity estimated in steps (ii) and (iii) and the concentration of the calibrator (C CAL ), estimate the concentration (C SOI ); in Step (b) is performed by a sequencer; Steps (i), (ii) and (iii) are performed by a data processing unit, which is connected to the sequencer; Step (d) is performed by a computing unit.
2. The method according to claim 1, wherein in steps (ii) and (iii), the sequence quantities assigned to the microorganism of interest and the calibrator, respectively, are normalized by a reference quantity.
3. The method according to claim 1, comprising taking into account a decision threshold (SD) which is intended to be related to the concentration (C SOI ) for comparison.
4. The method of claim 1, wherein the sample comprises an endogenous microorganism and the calibrator has a genome different from that of the endogenous microorganism.
5. The method of claim 1, wherein the genome size of the calibrator is 0.1 to 10 times the genome size of the microorganism of interest.
6. The method of claim 3, wherein the concentration of the calibrant is 0.001 to 1000 times the determination threshold.
7. The method of claim 3, wherein the concentration of the calibrant is 0.01 to 100 times the determination threshold.
8. The method according to claim 1, wherein step d) include: - determining a first ratio between the amounts of sequences assigned to said microorganism of interest and to said calibrator, respectively; - determining a second ratio between the respective genome sizes of said calibrator and said microorganism of interest; - Taking into account the concentration of the calibrator added to the analyzed sample.
9. The method of claim 8, wherein step d) comprises calculating the result of multiplying the first ratio by the second ratio and the concentration of the calibrator added to the analysis sample.
10. The method according to claim 1, wherein step d) include: - Determine the coverage of the microorganism of interest and the calibrator (Cov SOI , Cov CAL ); - calculating the ratio between the coverage determined for said microorganism of interest and the coverage determined for said calibrator; - multiplying the ratio thus calculated by the concentration of the calibrant added to the sample (C CAL ).
11. The method according to claim 3, further comprising a step e) after step d) of taking into account a decision threshold (SD) and comparing the concentration resulting from step d) with the decision threshold.
